SureTrader
Cannabis Stocks News
Interactive Brokers Advertisement
Home > Boards > US Listed > Biotechs >

Axsome Therapeutics (AXSM)

AXSM RSS Feed 		Add AXSM Price Alert      Hide Sticky   Hide Intro
Moderator: BioSpecialist
Search This Board: 
Last Post: 8/9/2017 10:14:45 AM - Followers: 15 - Board type: Free - Posts Today: 0

Undiscovered and massive undervalued Biotech Stock with many Big News on the way . Axsome has 5 Phase 3 in various indication targeting very large Markets including Alzheimer and Depression .This Stock is brutally undervalued with Market cap of $83 million and $50 million in cash .Founder and Ceo is the larget shareholder holding over 7 million shares (30%) over 50% of O/S is owned by Insider and Institutions which is a good sign .

This undiscovered Stock could be the next 10 bagger if only one of their 5 Phase 3 program is successful .GL


Axsome (AXSM)

Market-Cap: $83 Million
Cash: $50.6 Million (cash runway into the first quarter of 2019)
Price:$3.60

Shares Out: 23 Million


New Presentation March 31
http://phx.corporate-ir.net/External.File?item=UGFyZW50SUQ9NjY0Mzk1fENoaWxkSUQ9MzcyMTk4fFR5cGU9MQ==&t=1


Anticipated Near-Term Clinical Milestones:

Clinical Trial Initiations: -- Phase 2/3 clinical trial of AXS-05 in AD agitation (2Q 2017)

Clinical Trial Readouts:

-- Phase 3 COAST-1 trial of AXS-02 in knee OA associated with BMLs, interim analysis (3Q 2017)

-- Phase 3 CREATE-1 trial of AXS-02 in CRPS, interim efficacy analysis (4Q 2017)

-- Phase 3 STRIDE-1 trial of AXS-05 in TRD, top-line data (1Q 2018)



5x Phase 3 Programs in Pipeline :

AXS-02 COAST-1 Knee Osteoarthritis Associated with Bone Marrow Lesions in Phase 3 (SPA & Fast Track) ---7M patients in the U.S.


AXS-02 CREATE-1 Complex regional pain syndrome (CRPS) in Phase 3 (Orphan+Fast Track Status) ---No approved drug = high unmet need. 80,000 new cases per year in the U.S.


AXS-02 Chronic Low Back Pain Associated with Modic Changes in Phase 3 ---1.6M patients in the U.S.


AXS-05 Agitation in patients with Alzheimer’s disease(AD) in Phase 2/3 ---No approved medication = unmet medical need. 2M patients in the U.S.


AXS-05 STRIDE-1 Treatment resistant depression in Phase 3 ---Only 1 approved drug for TRD = unmet medical need. 3M patients in the U.S.



Major Shareholders
Herriott Tabuteau, MD 7 351 729 38,4%
Fidelity Management & Research Co. 2 361 625 12,3%
JPMorgan Asset Management (UK) Ltd. 1 432 456 7,48%
Mark Coleman, MD 647 998 3,38%
BlackRock Fund Advisors 426 837 2,23%
Stifel Trust Co., NA 415 279 2,17%
The Vanguard Group, Inc. 272 189 1,42%
Lombard Odier Asset Management (USA) Corp. 250 000 1,31%
JPMorgan Investment Management, Inc. 156 625 0,82%
SSgA Funds Management, Inc. 134 688 0,70%







the latest stock market analyst ratings:

Brean Capital began new coverage on Axsome Therapeutics, Inc. giving the company a “” rating. They now have a USD 20 price target on the stock.

Axsome Therapeutics, Inc. had its “” rating reiterated by analysts at Ladenburg Thalmann. They now have a USD 27 price target on the stock.

Cantor Fitzgerald began new coverage on Axsome Therapeutics, Inc. giving the company a “” rating. They now have a USD 13 price target on the stock.







Hey guys if you own shares of this low float stock then please put a high GTC sell order in to prevent your shares from being borrowed to short . This will help to drive this brutally undervalued stock much higher .Thank You
>>>>>>>>>>>>>>>>>>>>>How to Prevent your Shares Holdings from being Shorted<<<<<<<<<<<<<<<<<<<<<<
http://www.contracts-for-difference.com/Borrowing-lending-shares.html
 
SureTrader
Cannabis Stocks News
Interactive Brokers Advertisement
AXSM
Current Price
Volume:
Bid Ask Day's Range
AXSM Detailed Quote
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
SureTrader
AXSM News: Current Report Filing (8-k) 09/18/2017 07:02:18 AM
AXSM News: Axsome Therapeutics to Present at Upcoming Investor Conferences 09/18/2017 07:00:00 AM
AXSM News: Current Report Filing (8-k) 09/11/2017 04:08:47 PM
AXSM News: Axsome Announces CREATE-1 Interim Analysis Expected Year-End 2017 09/07/2017 07:00:00 AM
AXSM News: Amended Statement of Ownership (sc 13g/a) 08/10/2017 09:26:10 AM
PostSubject
#66   Options. chainma1l 08/09/17 10:14:44 AM
#65   Large insider buy djmurdock 08/08/17 05:05:23 PM
#64   Ladenburg Thalmann raised its price target on Axsome BioSpecialist 07/26/17 08:15:19 AM
#63   I'm not sure why AXSM isn't higher at chainma1l 07/25/17 10:12:26 AM
#62   Good News out today BioSpecialist 07/25/17 09:29:47 AM
#61   Axsome Therapeutics Appoints John Golubieski as Chief Financial Officer AHoldUp 07/06/17 07:37:16 AM
#60   Well, $AXSM is going north steady paced ... AHoldUp 06/27/17 08:49:47 AM
#59   Any ideas on the lock-up expiration dd 19th AHoldUp 06/21/17 04:42:09 AM
#58   Go Team Myrtle! mandymagoo 06/20/17 10:34:06 AM
#57   $5 is coming very close , good results BioSpecialist 06/20/17 09:50:24 AM
#56   Myrtle is our good luck charm! mandymagoo 06/20/17 09:33:09 AM
#55   the market like the news BioSpecialist 06/19/17 01:00:58 PM
#54   There are NO approved drugs for AD agitation BioSpecialist 06/19/17 10:22:10 AM
#53   Bio Specialist: spoke to a doctor last night--a redspinelpinktopaz 06/19/17 10:03:15 AM
#52   Great new Director, she really must like what BioSpecialist 06/19/17 09:13:25 AM
#51   Not widely followed. Has the potential to Rock_nj 06/19/17 05:16:00 AM
#50   Seems pretty cheap for being so deep in djmurdock 06/18/17 09:32:20 PM
#44   Q 3 is only a few weeks away. Rock_nj 06/09/17 01:35:49 PM
#43   Lot of buying alone in may by Institutional BioSpecialist 06/01/17 01:33:32 PM
#42   BioSpecialist Do you know the triggers and timing? DesireToLearn 05/24/17 06:33:23 PM
#41   Hello, new to this one. Do not own too simple 05/24/17 10:53:46 AM
#40   another nice move and stock is still flying BioSpecialist 05/22/17 11:45:33 AM
#39   they didnt know this stock but this will BioSpecialist 05/19/17 03:56:00 PM
#38   Why don't more people follow this board or DesireToLearn 05/19/17 03:34:05 PM
#37   RALLLLLLLLLLLLLLLLLLLY i love it hehe BioSpecialist 05/19/17 12:40:36 PM
#36   and another buy rating with tgt $14 BioSpecialist 05/19/17 09:27:19 AM
#35   look at the performance of the entire stock BioSpecialist 05/17/17 11:58:05 PM
#34   Any thoughts on the decline today? DesireToLearn 05/17/17 08:13:12 PM
#33   Another Guy likes AXSM ...more and more people BioSpecialist 05/16/17 09:14:43 AM
#32   Aegis Capital has reiterated a ‘Buy’ rating and BioSpecialist 05/12/17 09:18:03 AM
#31   AXSM ..Nice Article out by Napodano BioSpecialist 05/09/17 12:56:33 PM
#30   Yes, GREAT News, New Target is now???? BuyLowThenHold 05/08/17 11:06:16 AM
#29   Fantastic News out today... BioSpecialist 05/08/17 09:14:16 AM
#28   Thinking to make an investment here. Thoughts? DesireToLearn 05/07/17 01:26:12 PM
#27   GREAT NEWS indeed BioSpecialist 04/28/17 09:41:28 AM
#26   LYTTON LAURENCE W has filed a new 13G, wiltonio 04/27/17 03:17:00 PM
#25   Need to break the MA(50) at $4.24 then BioSpecialist 04/25/17 10:42:21 AM
#24   Load up guys while its still heavily underpriced BioSpecialist 04/20/17 12:22:18 PM
#23   Bullish crossover in MACD and Stochastic oscillator. BioSpecialist 04/13/17 11:53:01 AM
#22   Bigger jump in share price coming once it BioSpecialist 04/12/17 09:49:32 AM
#21   I told a friend or 2 as well. Hennypennyaz 04/11/17 03:46:46 PM
#20   looks like only a few people realize the BioSpecialist 04/11/17 03:27:34 PM
#19   Up she goes $5 coming guys BioSpecialist 04/11/17 09:55:54 AM
#18   looks like breakout is imminent BioSpecialist 04/10/17 02:08:27 PM
#17   this one will be over $10 before year BioSpecialist 04/07/17 10:01:02 AM
#16   Can somone summarize the conference. Out here in Hennypennyaz 04/05/17 09:24:04 AM
#15   First Phase 3 results expected within 3-4 months BioSpecialist 04/05/17 07:55:56 AM
#14   Unless I read this incorrectly next news will High jump 04/05/17 01:01:54 AM
#13   Looks like tree shaking to steal more cheap BioSpecialist 04/03/17 12:23:18 PM
#12   Hopefully people get in before. IMO Hennypennyaz 03/31/17 12:19:48 PM
PostSubject
© 2017 InvestorsHub.Com, Inc.